View as an RSS Feed
View Logical Assessment's Articles BY TICKER:
A Celgene Satellite: An Interview With Alliqua CEO Dave Johnson
- Alliqua recently raised $20.3 million in which Celgene participated.
- Changing landscape in medical reimbursement for wound care may serve as a boon to future sales.
- Alliqua CEO Dave Johnson shares his perspective.
Cardax Pharma: Addressing The Growing Inflammation Market With Nature's Answer
- Cardax Pharma has gone unnoticed due to its reverse merger method of going public.
- There is a clear development path for its product Astaxanthin in both nutraceuticals and pharmaceuticals.
- Astaxanthin demonstrates strong potential in TNF inhibition: a multi billion dollar market.
- Cardax has a strong partnership with BASF and backbone with Amgen.
- Cynapsus Represents A Compelling Acquisition Target For Acadia Pharmaceuticals
- San Fran Biotech Week Aftermath: Advaxis Is Primed To Take Off
- While Amarin Continues To Go Rancid, Neptune Will Soar
- The Immunotherapy Company You Never Saw Coming: Advaxis CSO Interview
- GlassesOff: The Most Disruptive Technology In Mobile
- Advaxis' S-1 Filing Foreshadows Imminent Uplisting To NASDAQ
- Organovo May Be Big Pharma's Salvation
- 6 Reasons Advaxis May Be The Best Reward Vs. Risk In Healthcare
- An Incredibly Asymmetric Risk/Reward Ratio For Sanuwave Foreshadows Huge Upside
- Has Illumina Set Its Sights On TrovaGene As Its Next Acquisition?
- As The Patent Cliff Approaches, Buy TrovaGene
- Sunshine Heart Quietly Reports Breakthrough In Congestive Heart Failure Treatment
- The 4 Healthcare Companies Investors Should Be Watching
- Why Royalty And Milestone Partnership Dynamics Imply Trovagene Could Triple
- Analyzing Market Efficiency: Why Future Catalysts Imply Sanuwave Still Has Room To Double
- ARM Holdings' Biotech Twin: FluoroPharma
- Biotech's Fallen Angels: Identifying Irrational Market Behavior
- The Shockwave Device That Heals: The SanuWave Opportunity
- Positive Top Line Data For Synergy: A Ripe Time For Acquisition
- Takeaways From Teva's Analyst Day: 'Restoring Shareholder Value'
- Is Sunshine The Solution To Device Tax Blues?
- Synergy CEO Reveals Why Investors Are Eagerly Anticipating Key Data
- Revisiting Buyout Rumors After Teva's CEO Shifts Focus To 'Smaller Acquisitions'
- Ironwood Implies Upside For Synergy; Lessons Learned From Dendreon